This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Management of Bleeding - EINSTEIN - Treatment of DVT and PE
Last updated : 05/16/2024
Eerenberg et al (2015) conducted a post hoc analysis to compare the severity of clinical presentation and clinical course for major bleeding with XARELTO vs LMWH/VKA in patients involved in the EINSTEIN studies.1
Efficacy Outcomes1
(N=8246)
|
Outcomes |
XARELTO |
LMWH/VKA |
|---|---|---|
|
Major bleeding episodes, n |
40 |
68 |
|
Number of times FFP was administered, n |
3 |
9 |
|
Number of times PCC was administered, n |
2 |
8 |
|
Number of times rFVIIa was administered, n |
1 |
- |
|
Erythrocyte transfusion for bleeds, % |
35 |
65 |
- In the analysis, vitamin K was given 28 times, but only once to a patient being treated with XARELTO.1
DVT, deep vein thrombosis; FFP, fresh frozen plasma; LMWH, low-molecular weight heparin; PCC, prothrombin complex concentrate; PE, pulmonary embolism; rFVIIa, recombinant factor VIIa; VKA, vitamin K antagonist.
LMWH, low-molecular weight heparin; VKA, vitamin K antagonist.
Reference
Show Hide
1. Eerenberg ES, Middeldorp S, Levi M, et al. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost. 2015;13(9):1590-1596.
